In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
21 authors.
Khalid N M AbdelazeemDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-0672-7900 Diemmy NguyenDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-2035-643X Sophia CorboDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-1179-6425 Laurel B DarraghDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-6445-7988 Mike W MatsumotoCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0009-0001-0618-7799 Benjamin Van CourtDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Brooke NeupertDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Justin YuDepartment of Otolaryngology - Head and Neck Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0003-2778-3175 Nicholas A OlimpoDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0001-6556-2168 Douglas Grant OsborneDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-6772-7031 Jacob GadwaDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0003-0560-2337 Richard B RossDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Alexander NguyenDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Shilpa BhatiaDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Mohit KapoorKrembil Research Institute, University Health Network, and University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-9877-0772 Rachel S FriedmanDepartment of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0001-7549-6387 Jordan JacobelliDepartment of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0001-6612-6704 Anthony J SaviolaDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Center, Aurora, CO, USA.ORCID 0000-0001-6890-512X Michael W KnitzDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-5786-9837 Elena B PasqualeCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-5076-4848 Sana D KaramDepartment of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0003-1676-5967 Funding
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8MTreating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.P50CA261605 · NCI · UNIVERSITY OF COLORADO DENVER · PI KARAM, SANA D · 2021 to 2025
$10.1MTackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCsR01DE028529 · NIDCR · WASHINGTON UNIVERSITY · PI SANA D KARAM · 2019 to 2026
$3.7MRegulation of transendothelial migration of Tregs in irradiated HNSCCs by EphB4-ephrinB2 interactionF31DE029997 · NIDCR · UNIVERSITY OF COLORADO DENVER · PI DARRAGH, LAUREL B · 2021 to 2023
$131kDivergent response to radio-immunotherapy in HNSCC and PDAC is mediated by regulatory T cellsF31DE033887 · NIDCR · WASHINGTON UNIVERSITY · PI Jacob Gadwa · 2024 to 2026
$85kNCI NIH HHS P50 CA261605NIDCR NIH HHS F31 DE029997NIDCR NIH HHS F31 DE033887NIDCR NIH HHS R01 DE028529NIDDK NIH HHS P30 DK116073
6 · The paper itselfAbstract
The EphB4-ephrinB2 signaling axis has been heavily implicated in metastasis across numerous cancer types. Our emerging understanding of the dichotomous roles that EphB4 and ephrinB2 play in head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to rational drug design. We find that EphB4 knockdown in cancer cells enhances metastasis in preclinical HNSCC models by augmenting immunosuppressive cells like T regulatory cells (Tregs) within the tumor microenvironment. EphB4 inhibition in cancer cells also amplifies their ability to metastasize through increased expression of genes associated with epithelial mesenchymal transition and hallmark pathways of metastasis. In contrast, vascular ephrinB2 knockout coupled with radiation therapy (RT) enhances anti-tumor immunity, reduces Treg accumulation into the tumor, and decreases metastasis. Notably, targeting the EphB4-ephrinB2 signaling axis with the engineered EphB4 ligands EFNB2-Fc-His and Fc-TNYL-RAW-GS reduces local tumor growth and distant metastasis in a preclinical model of HNSCC. Our data suggest that targeted inhibition of vascular ephrinB2 while avoiding inhibition of EphB4 in cancer cells could be a promising strategy to mitigate HNSCC metastasis.
Identifiers
PMID39091728
PMCPMC11291065
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390